Clinical trial
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
NCT00424489 · Northwestern University, Other · Terminated
Key facts
| NCT number | NCT00424489 |
|---|---|
| Title | Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis |
| Official title | Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis |
| Lead sponsor | Northwestern University, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myasthenia Gravis |
| Intervention type | Biological, Drug |
| Interventions | Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit), Mesna, Methylprednisolone, G-CSF |
| Enrollment | 9 |
| Start date | Feb 1, 2002 |
| Primary completion | Jun 1, 2016 |
| Completion | Jun 1, 2016 |
| First posted | Jan 19, 2007 |
| Last update posted | Aug 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: